君实生物股价连续3天上涨累计涨幅10.71%

Group 1 - The core viewpoint of the news is that Junshi Biosciences has seen a significant stock price increase, with a 10.71% rise over the past three days, closing at 37.82 CNY per share [1] - Junshi Biosciences is primarily engaged in the research and commercialization of monoclonal antibody drugs, with 90.67% of its revenue coming from drug sales [1] - The company was founded on December 27, 2012, and went public on July 15, 2020, with a current market capitalization of 38.829 billion CNY [1] Group 2 - Tianzhi Fund has a significant holding in Junshi Biosciences, with its Tianzhi New Consumption Mixed Fund (350008) holding 18,100 shares, representing 4.75% of the fund's net value [2] - The Tianzhi New Consumption Mixed Fund has generated a floating profit of approximately 66,200 CNY during the three-day stock price increase [2] - The fund was established on August 4, 2011, and has a current scale of 15.7711 million CNY, with a year-to-date return of 5.18% [2]